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ttp://dx.doi.org/10.1016/j.ajpath.2013.12.007Most patients with Parkinson disease (PD) develop both cognitive and motor impairment, and bio-
markers for progression are urgently needed. Although a-synuclein is altered in cerebrospinal ﬂuid of
patients with PD, it is not known whether it predicts motor or cognitive deterioration. We examined
clinical data and a-synuclein in >300 unmedicated patients with PD who participated in the deprenyl
and tocopherol antioxidative therapy of parkinsonism (DATATOP) study, with up to 8 years of follow-up.
Longitudinal measures of motor and cognitive function were studied before (phase 1) and during
(phase 2) levodopa therapy; cerebrospinal ﬂuid was collected at the beginning of each phase. Corre-
lations and linear mixed models were used to assess a-synuclein association with disease severity and
prediction of progression in the subsequent follow-up period. Despite decreasing a-synuclein (phase 1
to phase 2 change of 0.05  0.21 log-transformed values, P < 0.001), no correlations were observed
between a-synuclein and motor symptoms. Longitudinally, lower a-synuclein predicted better preser-
vation of cognitive function by several measures [Selective Reminding Test total recall a-synuclein 
time interaction effect coefﬁcient, 0.12 (P Z 0.037); delayed recall, 0.05 (P Z 0.002); New Dot
Test, 0.03 (P Z 0.002)]. Thus, a-synuclein, although not clinically useful for motor progression,
might predict cognitive decline, and future longitudinal studies should include this outcome for further
validation. (Am J Pathol 2014, 184: 966e975; http://dx.doi.org/10.1016/j.ajpath.2013.12.007)This work was supported by the Michael J. Fox Foundation, the Par-
kinson Study Group, and NIH grants NIEHS T32ES015459 (T.S.) and
AG033398, ES004696-5897, ES007033-6364, ES016873, ES019277,
NS057567, NS060252, NS062684-6221, and NS082137 (J.Z.).
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Disclosures: None declared.In addition to disabling motor symptoms that become more
severe over time, it is increasingly recognized that Parkin-
son disease (PD) progression also includes development of
signiﬁcant nonmotor symptoms. Of particular concern is
cognitive decline as the disease progresses, with most pa-
tients eventually developing dementia,1,2 with devastating
consequences for both patients and caregivers. However, the
natural course of motor and cognitive decline in PD can
vary substantially, with individual patients exhibiting slower
decline or precipitous decreases in motor or cognitive
function, likely depending on variation in the underlying
pathological characteristics. There is no method to identify
patients at risk of fast decline, and, because the mechanisms
by which it occurs are not understood, no treatments exist to
alter the course of the process.stigative Pathology.
.a-Synuclein (a-syn) is the primary component of the Lewy
bodies that are diagnostic of PD, and has been implicated in
the pathogenesis of PD by much evidence, including the
existence of early-onset familial forms caused by mutations
in its gene and consistent association with sporadic PD in
genome-wide association studies.3e5 Although mechanisms
remain to be investigated, a-syn protein has also been shown
in several large studies to be lower in the cerebrospinal ﬂuid
(CSF) of patients with PD and related synucleinopathies
CSF a-Syn in PD Progression(eg, Lewy body dementia and multiple system atrophy),
compared with controls.6e10 CSF a-syn does not typically
correlate with severity of motor impairment in studies with
large cohorts6,8,11; however, these were generally performed
in cross-sectional cohorts, often confounded by the exposure
of all subjects to dopamine therapy. Human studies to assess
the role of a-syn in cognitive decline or dementia are largely
an uncharted territory.
The deprenyl and tocopherol antioxidative therapy of
parkinsonism (DATATOP) study remains the largest cohort
assembled,with longitudinal collection of biological ﬂuid and
clinical data of patients with PD.12,13 DATATOP subjects
were recruited at early disease stages, without apparent signs
of dementia and before needing dopamine-supplementing
drugs, and were extensively characterized by longitudinal
clinical assessment, including measures of motor and cogni-
tive function, making this cohort ideal for studying PD pro-
gression. In addition, each subject contributed CSF samples
at two time points, allowing investigation of the question
of whether biomarkers at unmedicated baseline or the
beginning of levodopa therapy can predict motor or cognitive
progression.
This study examined the relationships between CSF a-
syn and measures of PD severity and progression. The
longitudinal alterations in CSF a-syn during unmedicated
PD progression were determined. Cross-sectional correla-
tions of CSF a-syn with motor and cognitive measures, at
early disease stages and after signiﬁcant PD progression,
were assessed. Finally, it was determined whether CSF a-
syn in early unmedicated PD, or just at the point at which
medication becomes necessary, predicts motor or cognitive
progression in the subsequent time period.
Materials and Methods
Subjects and Clinical Measures
Procedures were approved by all institutions participating in
the study, and written consent was obtained from all sub-
jects under the supervision of institutional review boards of
the study sites.
All subjects were participants in the DATATOP study, a
placebo-controlled, double-blind study to determine the
effectiveness of the monoamine oxidase type B inhibitor,
deprenyl, and the antioxidant, a-tocopherol, in delaying PD
progression. A total of 800 subjects with early, unmedicated
PD were recruited between September 1987 and November
1988. Subjects had mild PD symptoms not initially requiring
dopamine replacement, and did not meet the study criteria for
dementia [Mini-Mental Status Examination (MMSE) score,
<23]. Subjects were randomly assigned to one of four
treatment groups: placebo, deprenyl, a-tocopherol, or both
deprenyl and a-tocopherol. The primary end point was
deﬁned as the time at which a clinician (blind to the study
treatment group) determined that the subject’s PD motor
symptoms had progressed to the point of requiring levodopaThe American Journal of Pathology - ajp.amjpathol.orgtherapy. Many of the subjects who reached end point before
completion of their 24-month enrollment period were
restarted in blinded manner on their previously assigned
study drugs. After subjects had been followed up for an
average of 14 months, the study was discontinued because of
the observation that deprenyl had positive effects on pro-
gression of PD motor symptoms, and all subjects were
transitioned to open-label administration of deprenyl for
approximately 18 months.
Cognitive performance and other clinical measurements
[including the Uniﬁed Parkinson Disease Rating Scale
(UPDRS), MMSE, and Hoehn and Yahr scales] were
assessed at baseline, and then every 6 months afterward,
continuing after end point, for up to 6.9 years (average
follow-up, 1.8 years). Longitudinal data are separated into
phase 1, consisting of the time period beginning at study
entry until end point, and phase 2, beginning at the initiation
of levodopa therapy and continuing until the end of follow-
up. CSF samples were collected at entry into the study
(beginning of phase 1) and at the time of end point (beginning
of phase 2).
Previous studies did not detect differences in cognitive
decline between treatment groups14; therefore, all treatment
groups are included in this study. Because the current study
focused on changes in CSF biomarker levels, and cognitive
decline, for which changes caused by disease progression are
likely to be slow, 110 subjects with <6 months of follow-up
were excluded, as in a previous investigation.15 Also
excluded were those who withdrew after 6 months (34 sub-
jects), whose initial PD diagnoses were found to be incorrect
(45 subjects), and any subjects with missing UPDRS or CSF
data at the beginning of phase 1 (n Z 63) or phase 2
(nZ 189). The remaining 403 subjects were included in the
current analyses that examined data from phase 1. Of these
subjects, a total of 305 reached their end points by the end of a
deprenyl open-label trial and continued after starting levo-
dopa, and were thus included in phase 2 analyses.
Cognitive Measures
The DATATOP study included several measures of cogni-
tive performance. Only those for which longitudinal data
were available through the end of the follow-up period were
included in this study. These tests were as follows: total
and delayed recall selective reminding tests16 [Selective
Reminding Test (SRT)-Total and SRT-Delayed, respec-
tively; measures of verbal learning and memory], Symbol
Digit Modalities Test (SDMT17; a test of visuospatial
working memory/processing speed), and New Dot Test
(visuospatial working memory).
APOE Genotype
Genomic DNA was available from 199 DATATOP partici-
pants who participated in phase 2 analyses.APOE genotyping
was performed by using a matrix-assisted laser desorption/967
Stewart et alionization time-of-ﬂight mass spectrometry technology
combined with the homogeneous mass-extend reaction, as
previously described.18
CSF Assays
The procedure for CSF collection has been described else-
where.19 Brieﬂy, lumbar puncture was performed between 6
and 10 AM, and samples were collected in measured ali-
quots, which were immediately placed on ice until freezing
at 70C. All sites used the same collection procedures.
CSF samples remained frozen until immediately before
measurement of a-syn levels by Luminex assays (Luminex,
Austin, TX), according to our previously published pro-
tocol.6 All samples were evaluated using a LiquiChip
Luminex 200 Workstation (Qiagen, Hilden, Germany).
Hemoglobin (Hgb) was measured in all samples by ELISA
(Bethyl Lab, Inc., Montgomery, TX), according to the
manufacturer’s instructions. On the basis of our previous
ﬁndings that a-syn correlates strongly with Hgb in samples
with Hgb >200 ng/mL,6 samples exceeding this cutoff were
excluded from the analysis. Although the CSF samples used
in this study were archived samples (many were stored
frozen for >20 years), a-syn values were consistent with
those from more recently collected CSF measured by the
same method in previous studies.6
Analysis
Because subjects began levodopa therapy after the end of
phase 1, UPDRS scores (which are expected to be markedly
affected by drug treatment) are difﬁcult to interpret through
this transition. Furthermore, cognitive scores tended to
remain the same or increase during phase 1, and decline
over phase 2. This pattern could suggest that either cogni-
tive decline does not begin until later stages, or, because
many subjects actually had increases in cognitive test scores
over early trials, improvement with learning of the task
contributed signiﬁcantly to the outcome at this stage.
Therefore, to minimize the confounding due to contrasting
factors (eg, improvement as the result of learning the task
versus disease-related cognitive decline), phases 1 and 2
were analyzed separately. When examining longitudinal
changes in UPDRS scores and CSF a-syn during phase 1,
both subjects who reached the end point and those who did
not were included. However, to produce a more homoge-
neous cohort, only those subjects who reached end point by
the end of the open-label trial were included in cross-
sectional correlations or longitudinal analyses beginning in
phase 2 (ie, all subjects included had started drug therapy at
the beginning of this time period).
CSF levels of a-syn were log(10) transformed to
compensate for nonnormal distribution of the raw measure-
ments. Longitudinal changes in a-syn were assessed by
paired t-test. Cross-sectional correlations were determined
using partial correlation, controlling for age, sex, and, for968cognitive scores, level of education. Individual rates of
cognitive decline were calculated by linear regression for
subjects with ﬁve or more longitudinal test scores. To
determine whether CSF biomarker levels could predict lon-
gitudinal PD progression, as measured by UPDRS or
cognitive scores, linear mixed models were implemented
controlling for age, sex, education, PD severity, baseline
cognitive score, length of exposure to deprenyl, administra-
tion of tocopherol, and follow-up time, with the outcome of
interest being the a-syn  follow-up time interaction term.
To control for potential effects of levodopa therapy, levodopa
equivalent daily dose (LEDD) was determined, as previously
described,20e23 using the following calculation:
LEDDZðregular levodopa dose 1Þ
þ ðslow release levodopaÞ  0:75þ ðbromocriptine 10Þ
þ ðpergolide 100Þ þ amantadine 1:
Antihistamine and anticholinergic drugs were not included
in the calculation. Mean LEDD reﬂects the mean (daily)
LEDD over the whole phase 2 follow-up period. To control
for effects of deprenyl, including variable time of treatment,
we also controlled for length of exposure to deprenyl. Sta-
tistical tests are two tailed, with signiﬁcance level set at
PZ 0.05; however, some P values should be interpreted with
caution because of the involvement of multiple comparisons
in this study. All statistical analyses were performed using
IBM SPSS version 19 (Armonk, NY).
Results
Demographic and Clinical Measurements
Clinical and demographic data, as well as CSF a-syn levels,
at the beginning of phases 1 and 2, are presented in Table 1.
CSF samples from 350 subjects met the quality control
requirement of Hgb cutoff (200 ng/mL) at the beginning
of phase 1, as did 354 at the beginning of phase 2. Of these
subjects, 266 reached endpoint by the end of the open label
trial, and were included in Phase II analyses. Among sub-
jects whose CSF samples met the requirement at the
beginning of both phases 1 and 2 (a total of 304 subjects,
eliminating subjects in whom at least one CSF sample did
not meet quality control), the longitudinal increase (from the
beginning of phase 1 to the beginning of phase 2) in total
UPDRS score was 15.27  11.98, whereas motor scores
increased by 10.37  8.89. Baseline MMSE scores were
typically normal, with >84% of the cohort having scores of
28 or higher. CSF levels of a-syn signiﬁcantly decreased
over phase 1 (Figure 1), with a mean longitudinal change
of 0.05  0.21 (log-transformed values, paired t-test,
P < 0.001). The longitudinal decrease in CSF a-syn was
similar when the sample was restricted to only subjects
who reached end point during phase 1 (0.05  0.22,
P < 0.001). Cognitive scores typically remained stable or
increased slightly over the phase 1 period, and then tendedajp.amjpathol.org - The American Journal of Pathology
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Figure 1 Log-transformed levels of CSF a-syn at phase 2 as a function
of phase 1 level. Line represents no change from beginning of phase 1 to
beginning of phase 2.
Table 1 Demographic Characteristics of Cohort at Beginning of
Phases 1 and 2
Characteristics Phase 1 Phase 2
Age (years) 60.90  9.21 62.64  9.03
Range 34e79 37e80
Female/male ratio (% male) 128:222 (63) 90:176 (65)
Duration of disease (years)
Means  SD 2.08  1.39 3.80  1.45
Range 0e7 1e8
MMSE score*
Means  SD 28.86  1.44 28.74  2.30
Range 23e30 8e30
H&Y
Median 1.5 2.0
Range 1.0e2.5 1.0e4.0
UPDRS total
Means  SD 23.65  11.70 44.97  13.74
Range 0e63 8.5e88.0
UPDRS motor
Means  SD 15.85  8.80 30.24  10.41
Range 0e50 4.5e62
a-Syn (ng/mL)
Means  SD 0.63  0.73 0.47  0.18
Range 0.13e8.41 0.17e1.09
SDMT
Means  SD 40.21  10.90 39.38  11.72
Range 3e70 9e80
SRT-Total Recall
Means  SD 44.88  9.74 46.83  10.66
Range 19e71 12e71
SRT-Delayed Recall
Means  SD 7.31  2.67 6.87  2.90
Range 0e12 0e12
New Dot Test
Means  SD 12.80  1.46 12.65  1.44
Range 7e14 7e14
Data are given as means  SD unless otherwise indicated. Samples with
>200 ng/mL Hgb are excluded.
*Available only at phase 1.
H&Y, Hoehn and Yahr.
CSF a-Syn in PD Progressionto decline during phase 2. No differences in a-syn levels
were observed between treatment groups at phase 1 or
phase 2 (analysis of variance: phase 1, PZ 0.660; phase 2,
P Z 0.939).
Association of CSF a-Syn with Motor Symptoms
Cross-sectional correlation of CSF a-syn with UPDRS total
and motor scores, controlling for age and sex (both time
points), as well as exposure to deprenyl or tocopherol (at
phase 2 only), was performed for both the beginnings of
phases 1 and 2. No association was found between a-syn
and total or motor scores at either phase 1 (UPDRS total
correlation, 0.039, PZ 0.471; UPDRS motor correlation,
0.063, PZ 0.241) or phase 2 (total, 0.049, PZ 0.359;
motor, 0.051, P Z 0.347). In addition, the change in a-
syn level did not correlate with UPDRS obtained at theThe American Journal of Pathology - ajp.amjpathol.orgbeginning of phase 2 (data not shown), controlling for age,
sex, and exposure to study drugs.
The predictive value of CSF a-syn was also assessed,
using linear mixed models controlling for age, sex, and
UPDRS at baseline (for phase 1), or in the 6 months pre-
ceding CSF sample collection (for phase 2). For phase 2,
exposure to deprenyl or tocopherol in phase 1 was also
controlled. CSF levels at the beginning of each phase did not
signiﬁcantly predict UPDRS total or motor progression
during phase 1 (total: interaction coefﬁcient, 0.31  0.17,
P Z 0.070; motor: interaction coefﬁcient, 0.22  0.12,
P Z 0.055) or phase 2 (total: interaction coefﬁcient,
0.17  0.11, P Z 0.147; motor: interaction coefﬁcient,
0.10  0.08, P Z 0.181). Controlling for exposure to dep-
renyl in phase 1 and mean (daily) LEDD in phase 2 did not
affect the outcome (Supplemental Table S1). The change in
a-syn between phase 1 and phase 2 did not predict UPDRS
total or motor progression in phase 2, controlling for age, sex,
UPDRS, and exposure to study drugs, with or without con-
trolling for mean LEDD (data not shown).
Association of CSF a-Syn with Cognitive Decline
The cross-sectional association of CSF a-syn with cognitive
performance was also examined, considering age, sex, and
education, as well as study drug exposure (in phase 2), as
covariates (Table 2). At each time point, CSF a-syn was
associated only with a single memory test (SRT-Delayed in
phase 1; SRT-Total in phase 2).
The relationships between individual a-syn measures and
individual rates of cognitive decline (calculated initially using
linear regression) for each subject are shown in Figure 2. None
of the results demonstrated signiﬁcant correlations; however,
these data do not represent effects observed in the data in
aggregate when controlling for potential confounding vari-
ables. To account for these variables and assess the value of
CSF a-syn measured at the beginning of phase 1 or phase 2 in
predicting longitudinal cognitive decline in the following time
period, we used linear mixed models, controlling for age, sex,
education, exposure to study (ie, deprenyl or tocopherol) or969
Table 2 Cross-Sectional Association of Cognitive Scores with CSF
a-Syn
Test
Phase 1 Phase 2
Corrected
value P value
Corrected
value P value
SDMT 0.020 0.716 0.022 0.680
SRT-Total Recall 0.079 0.144 0.110 0.042
SRT-Delayed Recall 0.122 0.024 0.062 0.253
New Dot Test 0.004 0.938 0.002 0.968
Correcting for age, sex, and education at phase 1, as well as length of
exposure to deprenyl and exposure to tocopherol at phase 2.
Bold indicates signiﬁcance at the P < 0.05 level.
Stewart et altherapeutic (ie, mean LEDD) drugs, and test performance at
the beginning of the relevant time period (Table 3). CSF a-syn
at baseline did not predict cognitive outcome in any test over
phase 1, but CSF values at the beginning of phase 2 predicted
outcome over phase 2 in SRT-Total, SRT-Delayed, and New
Dot Test. The negative coefﬁcient indicates that a higher
marker value tends to predict a greater negative slope (faster
decline in cognitive score). Figure 3 shows the modeled
cognitive decline over phase 2 for subjects with mean, low, or
high (mean, mean  1 SD) CSF a-syn at the beginning of
phase 2. Thus, the model predicts that subjects with high CSF
a-syn show faster deterioration in cognitive performance
(Figure 3). To determine whether overﬁtting contributes to the
signiﬁcance of this result, sensitivity analysis was done by
excluding individual variables included in the model.
Remarkably, exclusion of age, sex, education, UPDRS, length
of deprenyl exposure, tocopherol treatment, and test perfor-
mance just before phase 2 did not meaningfully alter the test
outcome. Notably, the change in a-syn levels from phase 1 to
phase 2 did not predict cognitive outcome in any test (data not
shown).
To determine whether ApoE genotype further affects the
relationship, ApoE genotype was included in the model, and
the three-way interaction between ApoE genotype, follow-
up time, and CSF a-syn was considered (Table 4). A
marginally signiﬁcant interaction was observed in only one
of the eight (four tests in two time intervals) conditions, and
inclusion of ApoE genotype in the model did not change the
conclusion (signiﬁcant relationship between time and a-syn
or not) in any case.Table 3 Predictive Value of CSF a-Syn in Cognitive Decline
Test
Baseline: phase 1
Coefﬁcient SE P
SDMT 0.0445 0.0737 0
SRT-Total Recall* 0.1301 0.0950 0
SRT-Delayed Recall 0.0151 0.0276 0
New Dot Test 0.0062 0.0154 0
See Table 2 for the phase 2 results, with or without controlling for mean LEDD
*Controlling for age, sex, education, baseline UPDRS, baseline test score, leng
Bold indicates signiﬁcance at the P < 0.05 level.
970Although it is unclear how levodopa might affect cognitive
performance in PD, when drug treatment effects were
included in the model, neither mean LEDD main nor inter-
action (mean LEDD  follow-up time in phase 2) effects
were signiﬁcant, and the model was virtually unchanged
when mean LEDD was included (Supplemental Table S1).Discussion
The following are the most important ﬁndings of this study:
a-syn decreased signiﬁcantly over approximately 2 years of
follow-up in patients with PD, but did not predict the
worsening of motor symptoms (UPDRS) over phase 1 or
phase 2, and CSF a-syn level signiﬁcantly predicted pro-
gression of cognitive decline over the phase 2 follow-up
period, but not over phase 1.
a-Syn has consistently been shown to be decreased in
subjects with PD compared with controls,6,7,9,10,24,25 but
does not correlate with PD severity in cross-sectional studies,
when relatively large cohorts are analyzed.6,8,11 In this lon-
gitudinal cohort, we found a signiﬁcant decrease over 2 years
of PD progression. Considering that these subjects are at
early stages of the disease, these results suggest the decreases
in a-syn begin fairly early and are likely important in the
disease process. Whether this observation can be extended to
premotor phases of the disease, making progressive de-
creases in CSF a-syn, a useful biomarker for premotor PD in
at-risk populations,26,27 should be further probed. Although
the cause of lowered CSF a-syn in PD and other synuclei-
nopathies6,7,9,10,24,25 is not clear, one hypothesis is that a-syn
decreases because of its sequestration in Lewy bodies.
However, the apparent early onset of changes in CSF a-syn
may conﬂict with this notion, because, if it were true, the
change would be expected to follow the progression of Lewy
pathological characteristics, which, in fact, reﬂects the
severity of clinical outcome throughout the course of the
disease (described later).
A negative, but important, observation is that, although a-
syn decreased as the disease progressed, its values did not
correlate with UPDRS scores, cross-sectionally or longitu-
dinally. It is notable that even in longitudinal assessments,
in which biological deterioration is readily apparent by pa-
tients’ increasingly severe symptoms, overall decreasingFinal: phase 2
value Coefﬁcient SE P value
.546 0.1071 0.0707 0.131
.183 0.1240 0.0590 0.037
.587 0.0516 0.0166 0.002
.686 0.0326 0.0103 0.002
.
th of exposure to deprenyl, and exposure to tocopherol.
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Figure 2 Individual slope of cognitive decline assessed by SDMT (A), SRT-Total (B), SRT-Delayed (C), or New Dot Test (D) as a function of log a-syn at the
beginning of phase 2. Includes subjects meeting criteria for phase 2 analysis who had ﬁve or more test results for calculation of slope. Dotted lines show
correlation. Solid lines represent a slope of 0 (no change in test score). Slopes were generated from linear regression for visualization only, and do not
represent effects observed in the data in aggregate when controlling for several confounding variables.
CSF a-Syn in PD Progressiona-syn values did not associate with increasingly severe
motor scores, suggesting that there is not a straightforward
relationship between CSF a-syn and motor symptoms. As
discussed earlier, similar observations have been made in
previous cross-sectional investigations,6,8,11 and have been
attributed, at least in part, to drug treatments, because these
medicines invariably mask motor scores to some extent. In
this study, even at the beginning of phases 1 and 2, when no
dopamine drugs were given to any subject, no correlation was
observed. One possible explanation is that UPDRS reﬂects
primarily deﬁcits arising from nigrostriatal degeneration,
whereas CSF a-syn levels are inﬂuenced by the whole brain
(and, in fact, the range of cognitive deﬁcits interrogated
herein may also reﬂect widespread cortical involvement).
Therefore, a-syn levels may serve better as a proxy for total
brain pathological characteristics (see sections dealing with
cognitive impairment later) than for motor-speciﬁc pro-
cesses. The caveat, of course, is that drug effects, especially
during phase 2, when all subjects received dopamine
replacement therapy, mask symptom severity. Although, in
theory, this issue can be further addressed by comparing
medicated with unmedicated subjects at more advancedThe American Journal of Pathology - ajp.amjpathol.orgstages, its clinical relevance becomes questionable, because
all patients with PD eventually require levodopa therapy, as
was observed in the DATATOP investigation.
The most important result of this study is the ﬁnding that
CSF a-syn level predicts cognitive decline. The tests used in
this study encompass multiple modes of cognition,
including verbal learning and memory, and visuospatial
working memory, suggesting that a-syn potentially reﬂects
changes in multiple regions associated with cognition.
However, although the trend was in the same direction in
phase 1 as in phase 2, it was only signiﬁcant in phase 2. This
could arise from several aspects of the cohorts, particularly
the earlier disease stage at phase 1, or the much longer
follow-up of phase 2. Alternatively, one might argue that the
accelerated cognitive decline during phase 2 might be
related to levodopa therapy. Indeed, negative effects of
levodopa on cognition have been suggested in animal
studies,28 but the relevance in humans is not clear.29,30 In
the DATATOP cohort, no interaction was detected between
LEDD and cognition, and inclusion of LEDD as a relevant
variable did not change the conclusions (Supplemental
Table S1). Thus, we believe the more signiﬁcant correlation971
Figure 3 Modeled cognitive decline over follow-up period for low (means  1 SD; blue line), mean (black dashed line), and high (means þ 1 SD; red line)
CSF a-syn.
Table 4 Three-Way Interaction Effect of ApoE Genotype on
Model of Cognitive Decline
Test
Phase 1 Phase 2
Coefﬁcient SE
P
value Coefﬁcient SE
P
value
SDMT 0.081 0.270 0.763 0.096 0.197 0.628
SRT-Total* 0.362 0.268 0.183 0.216 0.167 0.198
SRT-Delayed 0.134 0.084 0.113 0.098 0.048 0.042
New Dot Test 0.038 0.046 0.405 0.019 0.030 0.533
*Controlling for age, sex, education, baseline UPDRS, baseline test score,
length of exposure to deprenyl, and exposure to tocopherol.
Stewart et albetween a-syn and cognitive decline during phase 2 is likely
because of a longer follow-up and disease progression, rather
than dopamine replacement therapy.
Whether a-syn plays a direct role in development of
cognitive impairment in PD is not known, but given the
proposed role of a-syn in synaptic transmission,31 it is
possible that altered a-syn metabolism may be an important
factor. Several studies have shown that a greater burden of
Lewy bodies in the cortex is associated with dementia.32e34
Alterations in CSF a-syn have been observed in Lewy
body dementia compared with control subjects.7,8,10 None-
theless, the direction of the prediction of cognitive decline
(ie, the ﬁnding that low CSF a-syn predicts slower progres-
sion) is somewhat counterintuitive. Several large cross-
sectional studies have found that patients with PD and
other synucleinopathies have lower levels of CSF a-syn than
controls. Therefore, it might be expected that subjects with
more severe PD, regardless of whether severity is measured
by motor or cognitive scores, might be expected to have the
lowest CSF levels if CSF a-syn levels continue to decrease as
the disease advances. Although few studies have examined
the relationship between CSF a-syn and cognition, one study
found a positive correlation between a-syn and MMSE in
patients with Lewy body dementia.35 In contrast, our recent
study of a-syn, comparing CSF levels in patients with972Alzheimer disease and mild cognitive impairment with
controls, found a negative correlation (ie, lower a-syn levels
were associated with greater cognitive function).36 The
decreasing level of CSF a-syn in PD may be the result of
cellular mechanisms for sequestering a-syn, particularly the
pathological soluble species that have been suggested to be
the most toxic.37 However, as previously mentioned, this
idea conﬂicts with the ﬁnding that a-syn does not typically
correlate well with disease severity, whereas Lewy body
pathological features increase with progression. Instead,
these results support the hypothesis that the decrease in CSF
a-syn is the result of a compensatory process. In this model,
those with the lowest levels would be those best able to retainajp.amjpathol.org - The American Journal of Pathology
CSF a-Syn in PD Progressiona-syn, particularly in an environment where some portion of
the total a-syn is rendered nonfunctional by aggregation or
post-translational modiﬁcation. Also, they would receive the
most beneﬁt from whatever protective physiological effect
drives the process, resulting in a CSF analyte level most
dissimilar to controls, but enjoying less severe clinical
symptoms or progression than those with more normal-
appearing CSF. Thus, the retained a-syn would maintain
the normal physiological roles of the protein, which, although
not fully understood, are suggested to be important for
cognitive functions, including memory,38 through a variety
of potential mechanisms, including their proposed role in
dopamine metabolism.31,39e41 Through such a mechanism,
damaged or degenerating neurons might maintain their
function for a longer period than would those in subjects with
less efﬁcient a-syn retention, and subsequent higher CSF
levels. Although we cannot determine from the current work
which species of a-syn are involved, it does suggest a novel
interpretation of lowered a-syn in the CSF of patients with
PD, speciﬁcally that the driving mechanism may not be
minimization of toxicity by pathological species, but reten-
tion of functional a-syn, possibly at synapses throughout the
brain, even before signiﬁcant neurodegeneration (Figure 4).
Presumably, such a process would be secondary to other
disease effects (eg, genetic and environmental factors
affecting the production, release, and clearance of a-syn in
the brain), but what these processes may be remains to be
determined.
In addition to LEDD treatment in all patients with PD,
several additional caveats must be considered. First, because
the original study was targeted at comparing treatments in
patients with PD, no neurologically normal controls were
included in the DATATOP study. Ideally, all of the changesThe American Journal of Pathology - ajp.amjpathol.orgwe describe herein must be conﬁrmed in cohorts including
healthy controls for comparison. However, these results are
an important ﬁrst step. Because of the expense, difﬁculty,
and need for repeated invasive CSF collections in sick
subjects required for longitudinal studies of neurodegener-
ative disease, these results, using available resources, are an
encouraging prelude to larger studies. Second, tests to
extensively probe multiple modes of cognitive function
were not included in the study, and of those that were
included, only a few were administered after phase 1. We
have limited analysis to those that were continued in phase 2
and, thus, many aspects of cognition were not analyzed in
this study. In addition, several measurements were made on
the basis of multiple tests, and when multiple comparisons
are corrected for, some of the results would not reach sta-
tistical signiﬁcance. That being said, because longitudinal
studies of cognition in PD are difﬁcult, and few large co-
horts are available, such hypothesis-generating work is vital,
and necessary for the development of more targeted studies
of future cohorts. Hopefully, the results obtained in such a
large cohort can be validated further in a totally independent
cohort (eg, those being enrolled in additional large studies,
such as the PD Progression Markers’ Initiative in-
vestigations). These results should be considered for repli-
cation when the longitudinal samples become available in
the coming years. Finally, although the inclusion criteria
required exclusion of subjects with dementia at recruitment,
the study began before assessment of mild cognitive
impairment (MCI) became standard for studies of early PD.
Therefore, some subjects included may have met current
deﬁnitions of MCI, but that information is not available for
inclusion in the analysis. However, several lines of evidence
indicate that MCI was not a major contributor to the resultsFigure 4 Hypothesized driving mechanisms for
a-syn depletion from CSF in PD. Under normal
conditions, brain mechanisms for a-syn produc-
tion, release, and clearance combine to generate
normal a-syn homeostatic conditions (1). In PD
pathogenesis, an unknown fraction of a-syn be-
comes pathological (2). Cells respond to the
presence of pathological a-syn by sequestering
toxic species in Lewy bodies (3). Less functional a-
syn is, therefore, available in the cell. The ho-
meostatic balance is shifted toward retaining more
functional protein within the cell, to maintain
cellular function (4). The shift in homeostasis re-
sults in lower CSF levels of a-syn, but maintains
higher (more normal) levels of functional a-syn at
the synapse, resulting in improved maintenance of
normal synaptic activity (5).
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Stewart et alobserved in this study. A total of 84% of the subjects had
MMSE scores >28 at baseline, showing no obvious
cognitive dysfunction, and inclusion of baseline MMSE as a
covariable in the predictive models for cognitive decline had
little effect on the model (data not shown). Moreover,
typical AD markers tau, phosphorylated tau, and Ab1-42,
which are altered in the CSF by the time MCI appears in
AD, were examined in the same cohort.15 In this cohort, AD
biomarker levels at baseline and at the beginning of phase 2
were consistent with those in control populations,15 sug-
gesting that no prominent AD-type pathological feature is
present.
In summary, several major observations have been made
in this precious longitudinally collected set of CSF samples,
along with clinical data, of patients with PD. The most
important discovery centers on the ﬁnding that CSF a-syn
predicts cognitive decline, and may be a useful tool in
identifying patients at risk of faster progression of cognitive
dysfunction. a-Syn level decreased as PD progressed; yet, it
is those with higher a-syn levels who experienced faster
cognitive decline. This observation, if conﬁrmed, especially
in drug-naïve patients or relevant animal models, could shed
more light in understanding PD pathogenesis.Acknowledgments
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